Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Arie Belldegrun
Age : 71
Public asset : 74,300,428 USD
Country of residence : Unknown
Linked companies : Ginkgo Bioworks Holdings, Inc. - Allogene Therapeutics, Inc. - Kronos Bio, Inc. - UroGen Pharma Ltd.

Biography of Arie Belldegrun 
Arie S. Belldegrun is an entrepreneur and businessperson who founded 6 companies, among them: Kite Pharma, Inc., Allogene Therapeutics, Inc. and Agensys, Inc. and who has been at the head of 16 different companies. Presently, he holds the position of Chairman & Partner at Two River Group Holdings LLC, Chairman for Two River Group Management LLC, Chairman at Bellco Capital LLC (which he founded in 2003), Chairman at Two Rivers Consulting Corp., Chairman for UroGen Pharma Ltd., Chairman & Partner at Two River Consulting LLC, Executive Chairman of Allogene Therapeutics, Inc. (which he founded in 2017), Chairman of Kronos Bio, Inc., Co-Chairman at Breakthrough Properties LLC, Senior Managing Director at VV Manager LLC (which he founded in 2017), Senior Managing Director at Vida Ventures LLC (which he founded in 2017) (a subsidiary of VV Manager LLC) and Chairman of Technology Assessment Group. Arie S. Belldegrun is also Director & Professor at UCLA Institute of Urologic Oncology, Head-Urologic Oncology Division at David Geffen School of Medicine and Senior Managing Director at Vida Ventures LLC (he founded the company in 2017) and on the board of 5 other companies. Dr. Belldegrun previously was Chairman of Arno Therapeutics, Inc. and Non-Executive Chairman at Arno Therapeutics, Inc. (a subsidiary of Arno Therapeutics, Inc.), Chairman, President & Chief Executive Officer at Equinor ASA, Director at Agensys, Inc. (he founded the company in 1997), Executive Chairman, President & CEO at Kite Pharma, Inc. (he founded the company in 2009), Chairman-Molecular Biological Technology Committee at American Urological Association Education & Research, Inc., Researcher at National Cancer Institute and Member of Los Angeles Economy & Jobs Committee. Arie S. Belldegrun received a doctorate from The Hebrew University Hadassah Medical School and a graduate degree from Weizmann Institute of Science.


Current positions of Arie Belldegrun 
Holdings of Arie Belldegrun 
Arie Belldegrun : Personal Network 
Most Read News 
01/18ELON MUSK : Tesla investors urge judge to order Musk repay $13 billion for SolarCity deal
RE
01/14ELON MUSK : Musk says Tesla to accept dogecoin for merchandise
RE
01/27ELON MUSK : human-like robots and self-driving cars
RE
01/20ALAN JOPE : Unilever strategy under scrutiny after short-lived GSK skirmish
RE
01/27BERNARD ARNAULT : LVMH has pricing power to counter inflation, but must be reasonable-Arnault
RE
01/24ELON MUSK : Tesla countersues JPMorgan, claims bank sought 'windfall' after Musk tweet
RE
01/23NELSON PELTZ : Nelson Peltz's Trian builds stake in Unilever - source
RE
01/28CATHIE WOOD : Cathie Wood's ARK buys the dip in Tesla shares after months of selling
RE
01/26WILLIAM ACKMAN : Ackman's Pershing Square takes new position in Netflix
RE
01/25JOHN HESS : Hess Corp sees higher capital spending, production in 2022
RE
More news


© 2022 People and Ownership :   
Arie Belldegrun : Connections 


Latest news about Arie Belldegrun 
01/14INSIDER BUY : Allogene Therapeutics
MT
2021Ginkgo Bioworks, Inc. completed the acquisition of Soaring Eagle Acquisition Corp. from Eagle Equity Partners III, LLC and others.
CI
2021Ginkgo Bioworks, Inc. entered into definitive agreement to acquire Soaring Eagle Acquisition Corp. from Eagle Equity Partners III, LLC and others for $16.7 billion in a reverse merger transaction.
CI
2019Allogene Therapeutics, Inc. Appoints Rafael G. Amado as Executive Vice President of Research and Development and Chief Medical Officer
CI
2018Allogene Therapeutics, Inc. Announces Board of Directors
CI
2018Kronos Bio, Inc. announced that it has received $18 million in funding from Vida Ventures, Bellco Capital LLC, National Bank Investments Inc., and other investors
CI
2017Teva Pharmaceutical Industries Ltd. Announces Resignation of Arie Belldegrun as a Member of the Board of Directors
CI
More news